<unk>  has been tested as adjuvant treatment in nearly 200 breast cancer patients over a total of 5 years, and has shown to be safe and effective in Phase 2 trials. As a result, two additional<unk>  trials registered or underway are: (1) a 700 patient Phase 3 trial for FDA approval - not yet recruiting and (2) a 300 patient Phase 2 trial studying the combination of<unk>  and Herceptin® (trastuzumab).
NeuVax
Neurovax
Nextstrain
BrainGate
MedFlight
IKEA pencil
Valmy SAS
OpenNeuro